Centiva Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Centiva Capital’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,900	Closed	-$1.76M	–	1893
2022 Q3	$1.76M	Buy	+25,900	New	+$1.43M	0.03%	399
2021 Q1	–	Sell	-6,826	Closed	-$296K	–	1514
2020 Q4	$296K	Buy	+6,826	New	+$337K	0.01%	656
2020 Q3	–	Sell	-3,670	Closed	-$232K	–	923
2020 Q2	$232K	Buy	+3,670	New	+$252K	0.01%	475
2019 Q4	–	Sell	-7,295	Closed	-$354K	–	961
2019 Q3	$354K	Buy	+7,295	New	+$380K	0.02%	406

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Centiva Capital's GBT Position: Q4 2022 in Review

Centiva Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 25,900 shares — an estimated $1.76M sold.

Centiva Capital first reported a position in GBT in Q3 2019 and held it in 4 quarters. The position peaked at $1.76M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Centiva Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Centiva Capital sold 25,900 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $1.76M.
Centiva Capital first reported a position in Global Blood Therapeutics, Inc. in Q3 2019 and held it in 4 quarters.
Centiva Capital's Global Blood Therapeutics, Inc. position peaked at $1.76M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Centiva Capital's 13F filing for Q4 2022, filed 14 Feb 2023.